Is there a Bearish outlook for Vitae Pharmaceuticals Inc (NASDAQ:VTAE) this week?

September 13, 2017 - By Hazel Jackson

 Is there a Bearish outlook for Vitae Pharmaceuticals Inc (NASDAQ:VTAE) this week?

Vitae Pharmaceuticals Inc (NASDAQ:VTAE) Ratings Coverage

Among 5 analysts covering Vitae Pharmaceuticals (NASDAQ:VTAE), 2 have Buy rating, 0 Sell and 3 Hold. Therefore 40% are positive. Vitae Pharmaceuticals had 7 analyst reports since August 8, 2015 according to SRatingsIntel. The rating was upgraded by Zacks to “Sell” on Saturday, August 8. The firm has “Buy” rating given on Thursday, March 17 by Stifel Nicolaus. The firm earned “Market Perform” rating on Thursday, August 4 by JMP Securities. On Wednesday, September 21 the stock rating was downgraded by Piper Jaffray to “Neutral”. The firm has “Market Perform” rating by Wells Fargo given on Thursday, September 15. Wells Fargo initiated the stock with “Outperform” rating in Friday, December 4 report. The company was initiated on Tuesday, April 12 by BMO Capital Markets. Below is a list of Vitae Pharmaceuticals Inc (NASDAQ:VTAE) latest ratings and price target changes.

It is down 0.00% since September 13, 2016 and is . It has underperformed by 16.70% the S&P500.

Vitae Pharmaceuticals, Inc. is a biotechnology company. The company has market cap of $605.66 million. The Firm is focused on discovering and developing small molecule drugs for diseases. It currently has negative earnings. It is engaged in developing a portfolio of product candidates through Contour, its structure drug discovery platform.

More notable recent Vitae Pharmaceuticals Inc (NASDAQ:VTAE) news were published by: which released: “Vitae Pharmaceuticals and Boehringer Ingelheim to End Collaboration and …” on July 27, 2015, also with their article: “Vitae Pharmaceuticals Announces Positive Top-Line Results From Initial Phase 1 …” published on September 08, 2015, published: “Vitae Pharmaceuticals Announces Appointment of Carole Sable, MD, as Chief …” on June 06, 2016. More interesting news about Vitae Pharmaceuticals Inc (NASDAQ:VTAE) were released by: and their article: “VITAE SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Announces the Investigation of …” published on September 23, 2016 as well as‘s news article titled: “Here’s Why Shares of Vitae Pharmaceuticals Inc Are Skyrocketing Today” with publication date: September 14, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.